Chemotherapy for advanced or recurrent XXXX .

@entity1204 @entity632 @entity1 @entity440 @entity242 @entity5 @entity957 @entity900 @entity189 @entity7828 @entity902 @entity11558
Studies of chemotherapy in advanced or recurrent @entity5 have focussed on ovarian, cervical, and @entity1204 . For celomic @entity189 of the ovary, a large number of cytotoxic agents have been shown to be active. Dramatic improvement in frequency of response with lesser improvement in survival has been noted with the use of @entity900 -based combination chemotherapy as compared to single alkylating agents. More recent studies have evaluated alternative ways to employ @entity900 : higher dose schedules, intraperitoneal administration, and @entity902 compounds with a potentially better therapeutic index. None has yet been shown superior to a combination of relatively low-dose @entity900 plus an alkylating agent with or without @entity632 . @entity900 remains the best studied and most active single agent in @entity1 with @entity957 . While a number of other agents have demonstrated moderate activity, no combination of drugs has as yet proved superior to single-agent @entity900 . In @entity1204 , @entity7828 and @entity632 are the most active agents. @entity440 , @entity900 , and @entity11558 appear to have moderate activity. No combination has yet been shown to be superior to single agents. Information on chemotherapy for less common gynecologic @entity5 is largely anecdotal. Two observations are of note. @entity900 -based combination chemotherapy is highly active against germ-cell neoplasms of the ovary. @entity900 also has definite activity against mixed @entity242 .
